Gilteritinib (ASP2215) Liposomes

Mfr.No.	DLL-0021, DLL-0021-1A-2ML, DLL-0021-1A-10ML
Description	Gilteritinib (ASP2215) is a small-molecule inhibitor of FLT3/AXL with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. Gilteritinib (ASP2215) is a highly selective FLT3 inhibitor that demonstrates activity against both FLT3-ITD and FLT3-TKD mutation subtypes and selectively inhibits FLT3 at concentrations roughly 800-fold lower than those required to inhibit c-Kit (230 nM). This product is a pre-formulated liposomal version of Gilteritinib (ASP2215) which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance; the lipid composition of the liposomes is the same as Doxil. For preclinical research use only.
Alternative Names	ASP2215; HY-12432; S7754
Average Size	70-120 nm
Hydration Solution	250 mM ammonium sulfate, pH 5.5
External Solution	MCR5N.2
Signaling pathway	FLT3 pathway (activity against FLT3-ITD and FLT-TKD mutational subtypes); AXL pathway
Concentration	2.5 mg/mL
Concentration Total Lipid	26.4 mM
Composition	HSPC/Chol/DSPE-mPEG2000 (56.2/38.5/5.3, mol/mol)
Cas Number	1254053-43-4
Types of Liposomes	Drug Loaded Liposomes
Target	FLT3/AXL

Have you used this product?

Combination SKU	Supplier No.	Volume	Your price	Quantity
BHB19400013-1	DLL-0021-1A-2ML	2 mL	$995		Add to Cart
BHB19400013-2	DLL-0021-1A-10ML	10 mL	$4095		Add to Cart